COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,903 Articles (22,568 medRxiv, 8,335 bioRxiv)

Most recent first Previous |  Page 1196: Articles 11951-11960  | Next

Potential COVID-19 vaccination opportunities in primary care practices in the United States
Basu, S., Weintraub, R., Ganguli, I., Phillips, R., Phillips, R., Bitton, A.
10.1101/2021.09.20.21263757 — Posted: 2021-09-22
Thrombotic adverse events reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database
Tobaiqy, M., MacLure, K., Elkout, H., Stewart, D.
10.1101/2021.09.12.21263462 — Posted: 2021-09-22 Discussion: Onsite
Identifying At-Risk Communities and Key Vulnerability Indicators in the COVID-19 Pandemic
Thais, S., Leibowitz, S., Rios Gutierez, A., Passarelli, A., Santo, S., Shipp, N.
10.1101/2021.09.19.21263805 — Posted: 2021-09-22
The Delta Variant Had Negligible Impact on COVID-19 Vaccine Effectiveness in the USA
Blaiszik, B., Graziani, C., Olds, J. L., Foster, I.
10.1101/2021.09.18.21263783 — Posted: 2021-09-22
Association of Initial Clinical Characteristics with the Need for the Intensive Care Unit and Hospitalization in Patients Presenting to the Emergency Department with Acute Symptomatic COVID-19
Zollinger, B., Newton, S., Freeman, J. Q., Moran, S., Montano Vargas, N., Ma, Y., Meltzer, A. C.
10.1101/2021.09.19.21263800 — Posted: 2021-09-22
Alterations in CD39/CD73 Axis of T cells associated with COVID-19 severity
Dorneles, G. P., Teixeira, P. C., da Silva, I., Schipper, L. d. L., Santana Filho, P. C., Rodrigues Junior, L. C., Bonorino, C., Peres, A., Fonseca, S., Monteiro, M., Boeck, C., Eller, S., Oliveira, T. F., Wendland, E., Romao, P. R.
10.1101/2021.09.18.21263782 — Posted: 2021-09-22
Genomic analysis of SARS-CoV-2 breakthrough infections from Varanasi, India
Zaveri, L., Singh, R., Basu, P., Banu, S., Mukherjee, P., Vishwakarma, S., Sahni, C., Kaur, M., Singh, N. K., Yadav, A. K., Yadav, A. K., Ashish, A., Mishra, S., Tiwari, S., Mishra, S. P., Vodapalli, A., Bollu, H., Das, D., Singh, P. P., Chaubey, G., Sowpati, D. T., Tallapaka, K. B.
10.1101/2021.09.19.21262487 — Posted: 2021-09-22
COVID-19 Acceleration and Vaccine Status in France - August 2021
Baunez, C., Degoulet, M., Luchini, S., Pintus, P., Teschl, M.
10.1101/2021.09.18.21263773 — Posted: 2021-09-22
Cardiovascular Risk Factors and Outcomes in COVID-19: Hospital-Based Prospective Study in India
Sharma, A. K., Baig, V. N., Sharma, S., Dalela, G., Panwar, R. B., Katoch, V. M., Gupta, R.
10.1101/2021.09.19.21263788 — Posted: 2021-09-22
Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge
Baden, L. R., ElSahly, H. M., Essink, B., Follman, D., Neuzil, K. M., August, A., Clouting, H., Fortier, G., Deng, W., Han, S., Zhao, X., Leav, B., Talarico, C., Girard, B., Paila, Y., Tomassini, J. E., Schodel, F., Pajon, R., Zhou, H., Das, R., Miller, J.
10.1101/2021.09.17.21263624 — Posted: 2021-09-22 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).